Trials / Completed
CompletedNCT01838590
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOF | Sofosbuvir (SOF) 400 mg tablet administered orally once daily |
| DRUG | RBV | Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-05-01
- Completion
- 2014-08-01
- First posted
- 2013-04-24
- Last updated
- 2015-05-22
- Results posted
- 2015-05-22
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT01838590. Inclusion in this directory is not an endorsement.